Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

Key Takeaway: Janux Therapeutics has announced that the first participant has been dosed in its Phase 1 study of JANX014. This marks a significant milestone for the company as it progresses in its clinical development. Further details about the study's objectives and expected outcomes have not been disclosed.